Biochemical Markers Observed in Epicor Studies

A major portion of Embria’s research on EpiCor has been with double-blind, placebo-controlled human trials, looking at clinical endpoints. These results were aimed at demonstrating statistically significant improvements of the consumer’s health, and have been published in peer-reviewed Medline-indexed journals. Although reduction in symptoms of upper respiratory track infection (URTI) and allergies were the main thrust of the research, the importance of clinical biomarkers in demonstrating the causes of these beneficial effects was also recognized, and some of these results are reported in this WHITE PAPER. 


Posted on WholeFoods Magazine Online, July 2, 2013

epicor-clinical_studies.pdf1.08 MB